Children with major chronic illnesses often have symptoms which can lead to difficulties tolerating feed.1-5

Research shows that 100% whey protein aids digestion and tolerance by supporting faster gastric emptying and reducing the frequency of vomiting.6-11

Nutrini Peptisorb Energy is an energy dense (1.5kcal/ml), liquid semi-elemental feed with 100% extensively hydrolysed whey protein and 50% MCT, designed for children with malabsorption, with high energy and/or low fluid needs.

Nutrini Peptisorb Energy

Nutrini Peptisorb Energy is a Food for Special Medical Purposes for use under medical supervision. Nutrini Peptisorb Energy is a peptide-based, energy dense (1.5kcal/ml), nutritionally complete, ready-to-use tube feed for children from 1 year onwards. Nutrini Peptisorb Energy is designed for the dietary management of disease related malnutrition in children with malabsorption and/or maldigestion. Nutrini Peptisorb Energy is available in 500ml packs.

Indications

For the dietary management of disease related malnutrition in children with malabsorption and/or maldigestion. Must be used under medical supervision. Suitable as a sole source of nutrition for children from 1 year onwards. For enteral use only.

PBS prescribing criteria

The Nutrini Peptisorb range is available on the Pharmaceutical Benefits Scheme (PBS). The Nutrini Peptisorb range is available as a Restricted Benefit for the dietary management of conditions requiring a source of medium chain triglycerides. To be eligible for a script, patients must meet the following PBS criteria:

PBS Information Nutrini Peptisorb Nutrini Peptisorb Energy
Clinical criteria Patient must have fat malabsorption due to:

  • Liver disease; OR
  • Short gut syndrome; OR
  • Cystic fibrosis; OR
  • Gastrointestinal disorders
Patient must have fat malabsorption due to:

  • Liver disease; OR
  • Short gut syndrome; OR
  • Cystic fibrosis; OR
  • Gastrointestinal disorders
Population criteria N/A Patient must be aged from 1-10 years inclusive
PBS Code 10375C 11110R
Maximum script quantity 8 x (8 x 500ml) 10 x (8 x 500ml)
Number of repeats 5 5

PBS prescribing criteria

The Nutrini Peptisorb range is available on the Pharmaceutical Benefits Scheme (PBS). The Nutrini Peptisorb range is available as a Restricted Benefit for the dietary management of conditions requiring a source of medium chain triglycerides. To be eligible for a script, patients must meet the following PBS criteria:

PBS Information Nutrini Peptisorb
Clinical criteria Patient must have fat malabsorption due to:

  • Liver disease; OR
  • Short gut syndrome; OR
  • Cystic fibrosis; OR
  • Gastrointestinal disorders
Population criteria N/A
PBS Code 10375C
Maximum script quantity 8 x (8 x 500ml)
Number of repeats 5
PBS Information Nutrini Peptisorb Energy
Clinical criteria Patient must have fat malabsorption due to:

  • Liver disease; OR
  • Short gut syndrome; OR
  • Cystic fibrosis; OR
  • Gastrointestinal disorders
Population criteria Patient must be aged from 1-10 years inclusive
PBS Code 11110R
Maximum script quantity 10 x (8 x 500ml)
Number of repeats 5

Nutricia’s paediatric peptide-based feeds

DISEASE RELATED MALNUTRITION

Nutrini Peptisorb


view factsheet

DISEASE RELATED MALNUTRITION

Nutrini Peptisorb Energy


view factsheet

Get in touch

For more information about Nutricia’s Paediatric range, please contact the Nutricia Clinical Care line (toll free): 1800 060 051.

Website: www.nutriciamedical.com.au

Alternatively, please email us using the contact form.

References
  1. Shaw V (Editor) Clinical Paediatric Dietetics, 4th Edition 2014. Wiley-Blackwell.
  2. Rogers EJ et al. Nutrition. 2003; 19(10): 865-8.
  3. Dziekiewicz MA et al. Adv Exp Med Biol. 2015; 873: 1-7.
  4. Del Giudice E et al. Brain Dev. 1999; 21(5): 307-11.
  5. Campanozzi A et al. Brain Dev. 2007; 29(1): 25-9.
  6. Brun AC et al. Clin Nutr. 2012; 31(1):108-12.
  7. Fried MD et al. J Pediar 1992; 120(4):569-572.
  8. Alexander DD et al. World J Gastrointest Pharmacol Ther. 2016; 7(2): 306-19.
  9. Khoshoo V et al. Eur J Clin Nutr. 2002; 56(7): 656-8.
  10. Meyer R et al. BMC Gastroenterol. 2015; 15: 137.
  11. Khoshoo V et al. 1996 22(1): 48-55.14